EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 62022TB0786
Case T-786/22: Order of the General Court of 27 July 2023 — Frajese v Commission (Action for annulment — Medicinal products for human use — Marketing authorisation for the medicinal product Spikevax — Marketing authorisation for the medicinal product Comirnaty — COVID-19 vaccine — No interest in bringing proceedings — No direct concern — No individual concern — Inadmissibility)
Case T-786/22: Order of the General Court of 27 July 2023 — Frajese v Commission (Action for annulment — Medicinal products for human use — Marketing authorisation for the medicinal product Spikevax — Marketing authorisation for the medicinal product Comirnaty — COVID-19 vaccine — No interest in bringing proceedings — No direct concern — No individual concern — Inadmissibility)
Case T-786/22: Order of the General Court of 27 July 2023 — Frajese v Commission (Action for annulment — Medicinal products for human use — Marketing authorisation for the medicinal product Spikevax — Marketing authorisation for the medicinal product Comirnaty — COVID-19 vaccine — No interest in bringing proceedings — No direct concern — No individual concern — Inadmissibility)
OJ C 329, 18.9.2023, p. 26–27
(BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
18.9.2023 |
EN |
Official Journal of the European Union |
C 329/26 |
Order of the General Court of 27 July 2023 — Frajese v Commission
(Case T-786/22) (1)
(Action for annulment - Medicinal products for human use - Marketing authorisation for the medicinal product Spikevax - Marketing authorisation for the medicinal product Comirnaty - COVID-19 vaccine - No interest in bringing proceedings - No direct concern - No individual concern - Inadmissibility)
(2023/C 329/38)
Language of the case: Italian
Parties
Applicant: Giovanni Frajese (Rome, Italy) (represented by: O. Milanese and A. Montanari, lawyers)
Defendant: European Commission (represented by: G. Gattinara and A. Sipos, acting as Agents)
Re:
By his action under Article 263 TFEU, the applicant seeks the annulment, first, of Commission Implementing Decision C(2022) 7163 final of 3 October 2022 granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for ‘Spikevax — elasomeran’, a medicinal product for human use and repealing Decision C(2021) 94(final) and, second, of Commission Implementing Decision C(2022) 7342 final of 10 October 2022 granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for ‘Comirnaty — tozinameran, COVID-19 mRNA vaccine (nucleoside-modified)’, a medicinal product for human use and repealing Decision C(2020) 9598(final).
Operative part of the order
|
1. |
The action is dismissed as inadmissible. |
|
2. |
Mr Giovanni Frajese shall pay the costs. |